☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update - January 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for January 2024 (PDF).

This issue notifies clinicians of the new safety and educational materials to support regulatory measures to reduce the harms from valproate in men and women under 55 years of age. This includes a patient information leaflet, a patient guide and an information page that collects all resources in one place.

This issue also advises clinicians that systemic fluoroquinolone antibiotics must now only be prescribed when other commonly recommended antibiotics are inappropriate. The MHRA has recently reviewed the existing measures in place to encourage safe prescribing and has now taken additional regulatory actions to update prescribing information for all systemic fluoroquinolones.

Also this month, clinicians are notified that systematic reviews and meta-analyses of randomised controlled trials have highlighted a dose-dependent increased risk of atrial fibrillation in patients using omega-3-acid ethyl ester medicines. These studies recruited patients with established cardiovascular diseases or cardiovascular risk factors but in this population the incidence of atrial fibrillation was 3.9% when active treatment was compared to placebo. It is recommended that patients are advised to seek medical attention if they develop symptoms of atrial fibrillation and if atrial fibrillation is confirmed the medicine should be discontinued permanently.

Lastly in this issue is a summary of letters to healthcare professionals in December. These generally related to supply issues and recalls.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - January 2024' by emailShare 'Drug Safety Update - January 2024' on FacebookShare 'Drug Safety Update - January 2024' on TwitterShare 'Drug Safety Update - January 2024' on MastodonShare 'Drug Safety Update - January 2024' on LinkedInShare 'Drug Safety Update - January 2024' on reddit

SMC Update - January 2024

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Setmelanotide (Imcivree®) has been rejected for use in the treatment of obesity and the control of hunger associated with genetically confirmed Bardet‑Biedl syndrome (BBS) in adults and children 6 years of age and above. The manufacturer failed to make a submission for this indication. In considering the product license and acquisition cost, it would be expected that this medicine would be prescribed and monitored by a specialist.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2024' by emailShare 'SMC Update - January 2024' on FacebookShare 'SMC Update - January 2024' on TwitterShare 'SMC Update - January 2024' on MastodonShare 'SMC Update - January 2024' on LinkedInShare 'SMC Update - January 2024' on reddit

Drug Safety Update - December 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for December 2023 (PDF).

This issue reminds clinicians of the risk of pathological gambling and other impulse control disorders associated with aripiprazole use. This reminder has been issued due to a rise in Yellow Card reports. Clinicians should ensure patients and their caregivers are aware to be alert to the development of new or increased urges to gamble and other impulse control symptoms, such as excessive eating or spending, or an abnormally high sex drive. In such cases, dose reductions or medication cessation may be required.

This issue also warns clinicians to be aware of the risk of cobalt sensitivity reactions seen in association with vitamin B12 (hydroxocobalamin and cyanocobalamin) treatments. The case reports have typically described skin reactions occurring within 72 hours of starting treatment. When such reactions arise, the risks and benefits of continued treatment should be reassessed. Treatment can be continued with appropriate advice and management of the reaction symptoms. Individuals with a known cobalt allergy should speak to a healthcare professional before starting B12 treatments.

Lastly in this issue is a summary of letters to healthcare professionals in November. These generally related to supply issues and recalls but also a reminder that as from January 2024 valproate containing medicines must not be started in new patients (male or female) younger than 55 years, unless two specialists independently consider and document that there is no other effective or tolerated treatment, or unless there are compelling reasons that the reproductive risks do not apply.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - December 2023' by emailShare 'Drug Safety Update - December 2023' on FacebookShare 'Drug Safety Update - December 2023' on TwitterShare 'Drug Safety Update - December 2023' on MastodonShare 'Drug Safety Update - December 2023' on LinkedInShare 'Drug Safety Update - December 2023' on reddit

SMC Update - December 2023

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Osilodrostat (Isturisa®) has been rejected for use in the treatment of endogenous Cushing’s syndrome in adults. The manufacturer failed to make a submission for this indication. In considering the product license, it would be expected that this medicine would be prescribed and monitored by a specialist.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - December 2023' by emailShare 'SMC Update - December 2023' on FacebookShare 'SMC Update - December 2023' on TwitterShare 'SMC Update - December 2023' on MastodonShare 'SMC Update - December 2023' on LinkedInShare 'SMC Update - December 2023' on reddit

Drug Safety Update - November 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for November 2023 (PDF).

This issue raises awareness that falsified Ozempic® and Saxenda® products have been found in the UK, including falsified pens containing insulin, which may lead to patient harm. Clinicians should be vigilant for symptoms linked to hypoglycaemia in patients who may have obtained a falsified product. Yellow Cards can be submitted and such products should be quarantined if possible. Patients who are concerned that the pens they have purchased might be falsified that they should not use the pens and report as a Yellow Card as well.

Clinicians involved in the prescription and supply of the COVID-19 treatment Paxlovid® (nirmatrelvir and ritonavir) are reminded of the risk of harmful drug interactions with the ritonavir component due to its inhibition of the enzyme CYP3A. As such it can interact with many commonly prescribed drugs. Prescribers should obtain a detailed patient history of current medications before prescribing.

Finally this month, healthcare professionals are reminded to remain vigilant for suspected adverse reactions and safety concerns associated with e-cigarettes and e-liquids, commonly known as vapes. Suspected adverse reactions should be reported to the Yellow Card scheme and patients should be encouraged to raise any safety concerns with a healthcare professional and can self-report using the Yellow Card scheme.

Lastly in this issue is a summary of letters to healthcare professionals in October. These generally related to supply issues and recalls.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - November 2023' by emailShare 'Drug Safety Update - November 2023' on FacebookShare 'Drug Safety Update - November 2023' on TwitterShare 'Drug Safety Update - November 2023' on MastodonShare 'Drug Safety Update - November 2023' on LinkedInShare 'Drug Safety Update - November 2023' on reddit

« Older Posts Newer Posts »

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.